Probucol

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Probucol
Probucol.png
Systematic (IUPAC) name
4,4'-[propane-2,2-diylbis(thio)]bis(2,6-di-tert-butylphenol)
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
MedlinePlus a611037
Legal status
?
Identifiers
CAS number 23288-49-5 YesY
ATC code C10AX02
PubChem CID 4912
DrugBank DB01599
ChemSpider 4743 YesY
UNII P3CTH044XJ YesY
KEGG D00476 YesY
ChEBI CHEBI:8427 N
ChEMBL CHEMBL608 YesY
Synonyms 2,6-di-tert-butyl-4-({2-[(3,5-di-tert-butyl-4-hydroxyphenyl)sulfanyl]propan-2-yl}sulfanyl)phenol
Chemical data
Formula C31H48O2S2 
Mol. mass 516.844 g/mol
 N (what is this?)  (verify)

Probucol is an anti-hyperlipidemic drug[1] initially developed in the treatment of coronary artery disease.

However, clinical trials were stopped after it was found that it may lower HDL in patients with a previous history of heart disease.

Probucol was initially developed in the 1970s by a chemical company to maximize airplane tire longevity. Probucol is associated with QT interval prolongation.

Mechanism[edit]

Probucol lowers the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism. Additionally, probucol may inhibit cholesterol synthesis and delay cholesterol absorption.[2] Probucol is a powerful antioxidant which inhibits the oxidation of cholesterol in LDLs; this slows the formation of foam cells, which contribute to atherosclerotic plaques.

It is believed to act at ABCA1.[3]

It also lowers levels of HDL.[4]

References[edit]

  1. ^ Yamamoto A (December 2008). "A Uniqe Antilipidemic Drug - Probucol". J. Atheroscler. Thromb. 15 (6): 304–5. doi:10.5551/jat.E621. PMID 19075491. 
  2. ^ "Probucol. Drugs.com web site. [1]
  3. ^ Favari E, Zanotti I, Zimetti F, Ronda N, Bernini F, Rothblat GH (December 2004). "Probucol inhibits ABCA1-mediated cellular lipid efflux". Arterioscler. Thromb. Vasc. Biol. 24 (12): 2345–50. doi:10.1161/01.ATV.0000148706.15947.8a. PMID 15514211. 
  4. ^ Miida T, Seino U, Miyazaki O, et al. (October 2008). "Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling". Atherosclerosis 200 (2): 329–35. doi:10.1016/j.atherosclerosis.2007.12.031. PMID 18279878.